What an amazing time-line we are looking at for the first half of the year for CTIX. Exact placement of many events is difficult to judge. Guess-estimates were made on the date of the PR and information in the PR. Sprinkle amongst this list continued updates from Kevetrin P1 at DF and BIDMC and a host of other unknown developments due to statements such as “ initial discussions with the National Cancer Institute and other university hospitals are underway”. Particularly difficult to place in a timeline is preclinical release/published data from BIDMC, University of Bologna etc. Things are heating up here over next 5 months. Here is my highly speculative chicken-scratch list:
February 2013
Announcement of SW cancer center sponsored studies in myeloma. From the 12/31 ” We have now signed a Non-Disclosure Agreement with the Cancer Center and are quickly moving forward with a Material Transfer Agreement. “
Announcement of an additional sponsored study at University of Bologna. A pure guess here but from the 12/31 PR The University has indicated they are interested in a second study of Kevetrin in combination with a compound of a major European pharmaceutical company. Stated before actual name of the University was disclosed. Remember disclosure of this co-operative effort was first announced in September 2012.
March 2013
Not sure how this will be dispensed to us but We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.” So let it be written so let it be said, potentially huge news here, IMO.
Late March to early April 2013
Prurisol PoC phase 2/3 in Europe starts! Second drug in to trials, huge news here IMO. Thanks Progressive
Late May early June 2013
ASCO! From 2/04 PR The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies. Again huge news here IMO.
Plus Splice these in to the First Half of 2013
Start of University of Bologna sponsored phase 1b trial “A Multi-Center, Open-Label, Phase 1B Study of Escalating Doses of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, with Cytarabine Adminstered A) Subcutaneously, or B) Intravenously, in Patients with Acute Myelogenous Leukemia (AML).”
Start of BIDMC phase 2 Kevetrin and sunitinib in RCC
And then Results Prurisol phase 2/3 PoC
AI
